![Gilberto Lopes: Few of the positive trials we have data for in lung cancer from ASCO24](https://oncodaily.com/pub/uploads/2024/02/download-66-e1717175906556.jpg)
Photo of Gilberto Lopes taken from med.miami.edu
May 27, 2024, 13:04
Gilberto Lopes: Few of the positive trials we have data for in lung cancer from ASCO24
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X: .
“Alright!
ASCO abstracts are out. Most plenary and oral are LBAs so not out yet. Let’s check a few of the positive trials we have data for in lung cancer.
HARMONi-A – ivonescimab, an anti-PD-1/VEGF bispecific antibody, added to chemo vs chemo alone after EGFR TKI shows clinically relevant improvement in PFS!
322 patients randomized. 85%+ has 3rd gen – HR 0.46 [0.34, 0.62], P < 0.0001. Clearly positive.
New options for treatment are welcome. No OS data yet. Trial from China. Shouldn’t matter. But that has created challenges for approval in the US recently.”
Source: Gilberto Lopes/X
Jun 30, 2024, 12:25